<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36656">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01698021</url>
  </required_header>
  <id_info>
    <org_study_id>Projet 12-081</org_study_id>
    <nct_id>NCT01698021</nct_id>
  </id_info>
  <brief_title>Quantification and Description of the Increase in Serum Troponin Following Acute Coronary Syndrome</brief_title>
  <acronym>QUANTUM</acronym>
  <official_title>Quantification and Description of the Increase in Serum Troponin Following Acute Coronary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Université de Sherbrooke</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The new assay of troponins T (highly sensitive troponins) detects concentrations much lower
      than before. Few data are currently available on their kinetics during acute coronary
      syndrome, especially in regard to the correlation with CK MB. The aim of the present study
      is to describe the kinetic of highly sensitive troponins in acute coronary syndrome, to
      correlate it with the concentration of CK MB, and possibly to evaluate their prognostic
      value with respect to infarct size .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who meet the inclusion criteria will have a highly sensitive troponins and CKMB
      assays q 8hr for the first day, and q 12h for the next 2 days. If clinically not indicated,
      the blood sample can be cancelled at any time, as in the case of a patient with an initial
      suspicion of acute coronary syndrome in which the final diagnosis is something else. Only
      patients with a definitive myocardial infarction will be analyzed.

      Subgroup analyses includes ST-elevation MI, Non ST-elevation MI, revascularization vs no
      revascularization, procedural myocardial infarction.

      Another analysis conducted is the correlation between the values ​​of troponin and infarct
      size by echocardiography (in patients who have an echocardiography 2-7 days post AND 2-6
      months post myocardial infarction)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">November 2013</completion_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Evaluation of troponins kinetic in acute coronary syndromes.</measure>
    <time_frame>72 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Unstable Angina</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All consecutive patients presenting to the emergency department or being hospitalized for
        any reason in which we suspect an acute coronary syndrome.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;= 18 years-old

          -  Clinical suspicion of an acute coronary syndrome; (will be analyzed only patients
             with aposteriori definitive diagnosis of unstable angina or myocardial infarction)

        Exclusion Criteria:

          -  none
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Farand, Md MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Sherbrooke</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul Farand, MD MSc</last_name>
    <phone>(819) 346-1110</phone>
    <phone_ext>9093 pagette</phone_ext>
    <email>paul.farand@usherbrooke.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Francis Bonenfant, resident</last_name>
    <phone>(819) 346-1110</phone>
    <phone_ext>4987 pagette</phone_ext>
    <email>francis.bonenfant@usherbrooke.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Sherbrooke, departement de cardiologie</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Farand, MD MSc</last_name>
      <phone>(819) 346-1110</phone>
      <phone_ext>9093 pagette</phone_ext>
      <email>paul.farand@usherbrooke.ca</email>
    </contact>
    <contact_backup>
      <last_name>Francis Bonenfant, MD</last_name>
      <phone>(819) 346-1110</phone>
      <phone_ext>4987</phone_ext>
      <email>francis.bonenfant@usherbrooke.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Paul Farand, MD MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>June 25, 2013</lastchanged_date>
  <firstreceived_date>September 28, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Creatine Kinase, MB form</keyword>
  <keyword>Troponin</keyword>
  <keyword>Acute coronary syndrome</keyword>
  <keyword>myocardial infarction</keyword>
  <keyword>Unstable angina</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Angina, Unstable</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
